WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Sk°yen
0213 Oslo
Norway

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New DDDs

Overview of new DDDs decided at the two previous meeting of the WHO International Working Group for Drug Statistics Methodology. Comments or objections to the DDDs from the latest meeting (temporary codes) should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology within the deadline. If no objections are received, the new DDD will be considered final and included in the ATC/DDD Index. The year of implementation in the ATC/DDD Index is given in the list.

ATC codeATC level name (INN/generic name)DDDUnit Adm.routeDeadline for objection to temporary DDDs 1) Implementation in ATC/DDD index if no objection is received
J05AX21imidazolyl ethanamide pentandioic acid90mgOFinal2019
P01BD51pyrimethamine, combinations75mg 5)PFinal2019
J05AX22kagocel60mgOFinal2019
A10AE54insulin glargine and lixisenatide402)PFinal2019
B02BX06emicizumab15mgP01.09.20182019
G03GA10follitropin delta12mcgPFinal2019
A10BK04ertugliflozin10mgO01.09.20182019
A07AA10colistin9MUOFinal2019
L04AA37baricitinib4mgOFinal2019
N05AX15cariprazine3mgOFinal2019
A07AA08kanamycin3gOFinal2019
P01AB07secnidazole2gOFinal2019
J01DD63ceftriaxone and betalactamase inhibitor23)PFinal2019
A05AA01chenodeoxycholic acid1gO01.09.20182019
C01CA27droxidopa1gOFinal2019
D11AH05dupilumab21.4mgP01.09.20182019
L04AC14sarilumab14.3mgPFinal2019
V03AE09patiromer calcium8.4gO01.09.20182019
R03DX08reslizumab 7.1mgPFinal2019
G04BD13desfesoterodine3.5mgOFinal2019
L04AA36ocrelizumab3.29mgP01.09.20182019
J01DB11cefroxadine2.1gOFinal2019
L04AC16guselkumab1.79mgP01.09.20182019
G03CA03estradiol1.53mgTD sprayFinal2019
J05AX17enisamium iodide1.5gOFinal2019
J01FA03midecamycin1.2gOFinal2019
J01MA23delafloxacin0.9gOFinal2019
A16AX15telotristat0.75gO01.09.20182019
J01DI03faropenem0.75gOFinal2019
R03DA12mepyramine theophyllinacetate0.6gOFinal2019
J01MA23delafloxacin0.6gPFinal2019
J01DH06tebipenem pivoxil0.56gOFinal2019
R03DX10benralizumab0.54mgP01.09.20182019
J05AX18letermovir0.48gO,P01.09.20182019
J01MA22tosufloxacin0.45gOFinal2019
J01MA19garenoxacin0.4gOFinal2019
J01MA07lomefloxacin0.4gOFinal2019
J01DD18cefteram0.4gOFinal2019
L04AA40cladribine0.34mgO01.09.20182019
J01MA15gemifloxacin0.32gOFinal2019
J05AR23atazanavir and ritonavir0.34)OFinal2019
P01BE03artesunate0.28gR01.09.20182019
P01BE02artemether0.28gR01.09.20182019
J05AC02rimantadine0.2gOFinal2019
J04AK06delamanid0.2gOFinal2019
G02AD06misoprostol0.2mgOFinal2019
A07DA06eluxadoline0.2gOFinal2019
A06AH05naldemedine0.2mgOFinal2019
A04AD14rolapitant0.18gO01.09.20182019
J05AX19tilorone0.125 gOFinal2019
M09AX07nusinersen0.1mgPFinal2019
H03AA05thyroid gland preparations0.1gOFinal2019
1) Final: indicates that the date for objection has expired
2) refers to insulin glargine
3) refers to ceftriaxone
4) refers to atazanavir
5) refers to pyrimethamine

Last updated: 2018-06-04